 |
|
|
| |
NO DETECTION OF VARIANTS BEARING NS5B S282T MERICITABINE (MCB) RESISTANCE MUTATION IN DAA TREATMENT-NAIVE HCV GENOTYPE 1-INFECTED PATIENTS USING ULTRA-DEEP PYROSEQUENCING (UDPS)
|
| |
| |
Reported by Jules Levin
AASLD
Nov 5-8 2011
SF
S. Margeridon,1 S. Le Pogam,2 T.F. Liu,1 B. Hanczaruk,3 B.B. Simen,3 N. Shulman,4 R.W. Shafer,1 I. Najera2
1Infectious Diseases and Geographic Medicine, Stanford University Medical School, Stanford, CA, USA; 2Virology Discovery, Pharma Research Early Development, Roche, Nutley, NJ, USA;3454 Life Sciences a Roche Company, Branford, CT, USA; 4Clinical Development Virology Genentech, South San Francisco, CA, USA
|
| |
|
|
|
|
|
